Latest news with #Xifaxan
Business Standard
02-06-2025
- Business
- Business Standard
Zydus Lifesciences gets USFDA nod for Rifaximin tablets
Zydus Lifesciences announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin tablets, 550 mg, under the reference listed drug (RLD) Xifaxan tablets, 550 mg. Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets will be produced at the Group's manufacturing facility at SEZ II, Ahmedabad. According to IQVIA MAT 2025, Rifaximin tablets had annual sales of USD $2,672.9 million in the United States. The group now has 427 approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on 17.21% rise in revenue from operations to Rs 6290.2 crore in Q4 FY25 over Q4 FY24. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Shares of Zydus Lifesciences shed 0.53% to Rs 924.95 on the BSE.
Yahoo
17-03-2025
- Business
- Yahoo
Bausch Health announces next steps in financining initiative
Bausch Health (BHC) Companies provided an update on its financing plans. The Company announced that it has engaged J.P. Morgan in connection with the Company's previously announced financing objectives. Any transactions would be subject to market and other conditions and there can be no assurance that the Company will be able to successfully complete any transaction on acceptable terms or at all. Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on BHC: Questions or Comments about the article? Write to editor@ Bausch Health Companies: Uncertain Future Amid Xifaxan Dependency and Strategic Ambiguities Bausch Health: Navigating Market Risks Amid Uncertain Product Acceptance Bausch Health Reports Strong 2024 Growth Amid Challenges Bausch + Lomb price target lowered to $17 from $18 at BofA Bausch Health Reports Strong 2024 Financial Performance
